July 29, 2019

ASCO Updates Adjuvant Endocrine Therapy Guidelines for Postmenopausal Women
There are currently three FDA-approved aromatase inhibitors indicated for adjuvant treatment of breast cancer (BC) in postmenopausal women: letrozole, anastrozole, and exemestane. The American Society of Clinical Oncology recently updated its clinical practice guidelines on adjuvant endocrine therapy for postmenopausal women with hormone receptor–positive BC. Read more.


Effect of Chemo Dose Among Early Breast Cancer Patients
Standard combination chemotherapy reduces mortality by about one-third in patients with early breast cancer. The optimal dosage and timing of these agents, however, is not known, and it has been hypothesized that dose-dense regimens may enhance tumor-cell kill rates, decrease tumor regrowth, and improve the chances of cure. Read more.

Drug Interactions Associated
With CDK 4/6 Inhibitors

CDK 4/6 inhibitors are a new class of agents indicated for the treatment of hormone receptor–positive and human epidermal growth factor receptor–negative breast cancer. A recent paper published in Cancer Treatment Review examined the propensity for these drugs to be involved in drug interactions, as well as their significance. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App